These experiments have been initiated following our present results discussed above, and it is our belief that identifying specific molecular pathways genome-wide along with clarifying role of the ~56 kDa CRMP2 protein will help in understanding how PACAP38 might function as a neuroprotective and/or potentially therapeutic agent in counteracting ischemia. This evidence concerns the gene DPYSL2 and ischemia.